Amphista Therapeutics
Generated by Meeveem AI
"Developing next generation targeted protein degradation medicines to remove disease causing proteins"
Cambridge
•51 - 250 Employees
•Biotechnology
About Amphista Therapeutics
Amphista develops medicines that use the body's natural waste disposal system to selectively destroy and remove disease causing proteins. Unlike traditional therapies that only temporarily block protein function, their proprietary Targeted Glue technology triggers complete elimination of pathogenic proteins, opening treatment possibilities for cancers and neurodegenerative diseases. The company's chemistry first approach creates degrader molecules with superior drug like properties, including oral bioavailability and brain penetration. Their lead programmes target acute myeloid leukaemia and non small cell lung cancer, with pipeline assets addressing oncology and neurodegeneration.
65
Team Members
2017
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where patients with severe diseases including cancer and neurodegenerative disorders have access to transformational medicines that completely eliminate disease causing proteins from their bodies.
Our Mission
At Amphista, our mission is to unlock the full potential of targeted protein degradation by applying proprietary Targeted Glue technology to develop a powerful new generation of transformational medicines for patients with severe diseases.